Printer Friendly

BIODYNAMICS NAMES SENIOR MANAGEMENT TEAM FOR NEW GERMAN ACQUISITION

 TAMPA, Fla., June 8 /PRNewswire/ -- Biodynamics International, Inc. (NASDAQ: BDYN) announced today the appointment of the senior management team of its recently formed subsidiary, Biodynamics International (Deutschland), GmbH, ("BID"). Formerly the Wound Care Division of Pfrimmer-Viggo GmbH, BID processes tissue allografts for a variety of surgical applications worldwide and manufactures an extensive line of surgical sutures.
 Werner Specht, Ph.D., has been named BID managing director, Karl Koschatzky, Ph.D., will oversee production and research and development activities, Martin Zentgraf, M.D., will direct marketing and product development and Robert Eckert has been appointed director of finance and administration.
 "We are extremely pleased with the caliber and expertise of BID's new senior management team," said Biodynamics International President and Chief Executive Officer John V. Hargiss. "Each member of the new senior management group possesses excellent credentials and an impressive record of achievement. We look forward to their contributions to the future of Biodynamics globally."
 Dr. Specht brings extensive managerial and technical expertise to his new position. Most recently, he was director of medical technology and marketing for Dragerwerk AG with worldwide responsibility for marketing, product management and acquisitions. He also served as division manager diagnostics and as a member of the managing board for Becton Dickinson GmbH with full profit and loss responsibility for the division's business in Germany, Austria and Switzerland. He was also a participant in several multinational task forces engaged in human resource, legal affairs and new product development activities.
 Dr. Specht received his doctorate in chemistry from the University of Gottingen.
 Dr. Koschatzky had been with Pfrimmer-Viggo since 1982. In 1984 he was given full responsibility for production, research and development and registration activities. He holds undergraduate and doctoral degrees in chemistry from the University of Erlangen. "Dr. Koschatzky's role with BID assures a smooth transition in the vital areas of production and R & D," said Hargiss. "The division's impeccable record of product performance and integrity is testimony to his excellent leadership."
 Dr. Zentgraf was previously marketing manager at Glaxo GmbH and head of the Altana Group, Byk Gulden Pharmaceuticals, with responsibility for product development and marketing of the company's gastroenterological product line. Dr. Zentgraf is a graduate physician of the University of Muenster.
 Eckert was most recently chief financial officer for Steiner-Optik GmbH. He was instrumental in the development and formation of Steiner's NASDAQ stock exchange U.S. holding company, Steiner Optics International. Steiner manufactures and markets field glasses and optical industrial components worldwide. Eckert was graduated from the University of Bayreuth with a degree in economics.
 Biodynamics International, Inc. processes, manufactures and distributes worldwide, specialty surgical products for neuro, orthopedic, cardiovascular, reconstructive and general surgical applications. The company is a Florida corporation with executive offices here. Biodynamics International (Deutschland) has processing and manufacturing facilities in Neunkirchen, Germany and executive offices in Erlangen, Germany.
 -0- 6/8/93
 /CONTACT: John V. Hargiss or Charles C. Dragone of Biodynamics International, 813-979-0016/
 (BDYN)


CO: Biodynamics International, Inc. ST: Florida IN: HEA SU: PER TNM

AW-JB -- FL005 -- 6658 06/08/93 15:32 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 8, 1993
Words:506
Previous Article:GIANT FOOD INC. ANNOUNCES SALES AND EARNINGS FOR PERIOD
Next Article:JOHN ALDEN FINANCIAL CORPORATION DECLARES SECOND QUARTER 1993 DIVIDEND OF 6 CENTS PER SHARE
Topics:


Related Articles
AMERICAN BIODYNAMICS ANNOUNCES ANNUAL MEETING RESULTS
AMERICAN BIODYNAMICS SHAREHOLDERS APPROVE MOVE OF COMPANY AND NAME CHANGE
BIODYNAMICS ANNOUNCES EXECUTIVE APPOINTMENTS
BIODYNAMICS REPORTS RECORD NINE MONTH REVENUES AND PROFIT
BIODYNAMICS' CFO RESIGNS DUE TO HEALTH REASONS
BIODYNAMICS COMPLETES GERMAN ACQUISITION
BIODYNAMICS REPORTS MID-YEAR RESULTS
BIODYNAMICS REPORTS RESULTS FOR SHORTENED FISCAL YEAR
BIODYNAMICS INTERNATIONAL MAKES ANNOUNCEMENT
BIODYNAMICS' CEO JOHN V. HARGISS RESIGNS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters